One-Shot gene therapy trial offers hope for Hard-to-Treat blood cancer
Disease control
Recruiting now
This early-stage trial is testing the safety of a new gene therapy called KLN-1010 for people with multiple myeloma that has returned after multiple treatments. The therapy aims to reprogram the patient's own immune cells inside their body to attack cancer cells. Researchers will…
Phase: PHASE1 • Sponsor: Kelonia Therapeutics, Inc. • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC